Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom?

Novo Nordisk shares are down roughly 70% from their 2024 high and trade at about 10x earnings, versus a five-year average near 24x. The company fell behind Eli Lilly on GLP-1 effectiveness and faced supply constraints, but is shifting toward a higher-volume, lower-price model with its GLP-1 pill and says it is developing new drugs. Novo Nordisk has started a $2.2 billion share repurchase program; its reported dividend yield is 4.6%, with a 33% payout ratio, though a business recovery may take time.

Analysis

The key question is not whether the weight-loss market is large, but whether NVO can convert pill-led volume into durable, profitable share. Lower prices may widen access while also resetting customer expectations and cannibalizing higher-priced injectables; headline prescription growth would therefore be insufficient without evidence on net price, mix, and contribution economics. Supply reliability is now a competitive weapon: if NVO secures capacity and distribution, it can recapture demand that previously leaked to alternatives, but capacity alone cannot offset weaker efficacy or Lilly’s prescribing advantage.

Near term (days to 1–3 months), the article’s valuation and buyback narrative may support sentiment, but neither establishes an earnings floor. The buyback is a use of capital, not independent proof of intrinsic value. Over 6–18 months, the thesis turns on pill uptake, realized pricing, supply, and clinical differentiation of pipeline candidates. A sharp prescription-share loss, price concessions without volume acceleration, or renewed supply constraints would undermine it. A low earnings multiple can also prove optically cheap if estimates are still falling.

Contrarian angle: a lower-cost oral option could expand the treated population rather than merely shift patients from injectables, but that is a hypothesis to test against net sales and patient persistence. Avoid treating PEP/KO’s category analogy as evidence; branded beverages and efficacy-led prescription drugs have different switching and innovation dynamics. The supplied 4.6% yield and 33% payout should be verified against current filings before assigning downside protection.

Key Decisions for Investors

• Consider a staged NVO long rather than a one-shot value purchase; add only as reported volume growth is accompanied by stable or improving net sales per patient and supply availability.
• Keep LLY as the relative benchmark, not an automatic short: track prescription share, comparative clinical data, and net pricing. A relative-value NVO/LLY position is only warranted after checking current valuation, estimates, and borrow/carry.
• Treat the buyback and quoted yield as secondary support. Verify repurchase pace, dividend coverage, and whether capital returns are competing with capacity investment or R&D.
• Falsification watch: cut the thesis if NVO’s prescription share continues to deteriorate, volume fails to compensate for lower realized prices, or guidance/earnings estimates are revised down again; reassess positively if pill uptake translates into sustained net-sales growth without material discounting.